Kyprolis 10 mg powder for solution for infusion
Sponsors
University Medical Center Hamburg-Eppendorf, Kite Pharma Inc., Medizinische Universitaet Innsbruck, Regeneron Pharmaceuticals Inc., AstraZeneca AB
Conditions
Multiple myelomaRelapsed Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaRelapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibodymultiple myelomarelapsed/refractory multiple myeloma
Phase 2
Phase 3
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
CompletedCTIS2024-510590-14-00
Start: 2023-03-03End: 2025-01-30Target: 400Updated: 2025-02-05
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingCTIS2024-511188-26-00
Start: 2024-12-20Target: 192Updated: 2025-09-12
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
Not yet recruitingCTIS2024-519504-27-00
Target: 40Updated: 2026-02-10
HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma
Not yet recruitingCTIS2025-524876-43-00
Target: 126Updated: 2026-04-29
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)
Not yet recruitingCTIS2025-523285-25-00
Target: 38Updated: 2026-04-30